Press Releases
Ventripoint Announces Appointment of Justin Leushner as CEO and Changes to the Board of DirectorsToronto, Ontario, November 4, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce it has appointed Justin Leushner as CEO of Ventripoint. Dr. George Adams has resigned as CEO and has been elected as Chairman of the Board of Directors of Ventripoint. Read More...
Ventripoint President Justin Leushner joined Steve Darling from Proactive’s New York studio to discuss his new role with the company and Ventripoint's exciting new developmentsVentripoint Diagnostics Announces U.S. FDA Clearance for VMS+ 3.0 Whole Heart Analysis SystemToronto, Ontario, October 17, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received U.S. Food and Drug Administration (FDA) clearance for the VMS+ 3.0 whole heart analysis system.
Read More... St. Michael’s Hospital to Receive VMS+ 3.0 Whole-Heart
|
For further information please contact:
Justin Leushner, CEO
Phone: (416) 848-4156
Email: jleushner@ventripoint.com
|